rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www
Company profile
Ticker
RMTI
Exchange
Website
CEO
Russell Ellison
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ROCKWELL MEDICAL TECHNOLOGIES INC
SEC CIK
Corporate docs
Subsidiaries
Rockwell Transportation, Inc. • Rockwell Medical India Private Limited ...
IRS number
383317208
SEC advisor number
801-72736
FINRA CRD number
158916
AUM ?
$234.04 mm
(as of 4 Sep 20)
Accounts
2,081
(as of 4 Sep 20)
Employees
13
(3 investment advisory or research)
Address
Rockwell Medical
30142 WIXOM ROAD
WIXOM
MI 48393
30142 WIXOM ROAD
WIXOM
MI 48393
Office hours
Monday - Friday, MO - THU: 8 A.M. - 6 P.M. & FRI : 8 A.M. - 12 P.M.
Phone
8004493353
RMTI stock data
Ownership
Owner | Title | From | %Ownership |
---|---|---|---|
Richmond, David, Scott | President | 09/2011 | 50-75% |
Curfman, Matthew, Jeremy | Senior Vice President of Investment Services | 09/2011 | 10-25% |
Pirner, Gary, Matthew | Chief Compliance Officer | 12/2018 | < 5% |
Latest filings (excl ownership)
10-K
2023 FY
Annual report
21 Mar 24
8-K
Regulation FD Disclosure
21 Mar 24
8-K
Results of Operations and Financial Condition
21 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund
8 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Rockwell Medical Announces Third Quarter 2023 Results
14 Nov 23
8-K
Regulation FD Disclosure
14 Nov 23
8-K
Departure of Directors or Certain Officers
17 Oct 23
8-K
Entry into a Material Definitive Agreement
21 Sep 23
Transcripts
RMTI
Earnings call transcript
2023 Q4
21 Mar 24
RMTI
Earnings call transcript
2023 Q3
14 Nov 23
RMTI
Earnings call transcript
2023 Q2
14 Aug 23
RMTI
Earnings call transcript
2023 Q1
15 May 23
RMTI
Earnings call transcript
2022 Q4
30 Mar 23
RMTI
Earnings call transcript
2022 Q3
14 Nov 22
RMTI
Earnings call transcript
2022 Q2
15 Aug 22
RMTI
Earnings call transcript
2022 Q1
17 May 22
RMTI
Earnings call transcript
2021 Q3
16 Nov 21
RMTI
Earnings call transcript
2021 Q2
17 Aug 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.76 mm | 7.76 mm | 7.76 mm | 7.76 mm | 7.76 mm | 7.76 mm |
Cash burn (monthly) | 400.00 k | 435.08 k | 579.00 k | 674.08 k | 1.25 mm | 830.50 k |
Cash used (since last report) | 2.39 mm | 2.60 mm | 3.47 mm | 4.03 mm | 7.49 mm | 4.97 mm |
Cash remaining | 5.36 mm | 5.15 mm | 4.29 mm | 3.72 mm | 271.45 k | 2.79 mm |
Runway (months of cash) | 13.4 | 11.8 | 7.4 | 5.5 | 0.2 | 3.4 |
Institutional ownership, Q2 2023
31.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 42 |
Opened positions | 15 |
Closed positions | 7 |
Increased positions | 11 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 14.13 bn |
Total shares | 9.28 mm |
Total puts | 120.40 k |
Total calls | 60.20 k |
Total put/call ratio | 2.0 |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 4.91 mm | $4.96 mm |
DVA DaVita | 1.28 mm | $0.00 |
Richmond Brothers | 422.62 k | $2.31 bn |
Armistice Capital | 385.00 k | $2.10 bn |
Renaissance Technologies | 349.12 k | $1.91 mm |
EAM Investors | 293.25 k | $1.60 bn |
Jane Street | 272.31 k | $1.49 bn |
Vanguard | 243.92 k | $1.33 bn |
Stratos Wealth Partners | 150.18 k | $819.96 mm |
BLK Blackrock | 119.16 k | $650.60 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Mar 24 | Mark Strobeck | Common Stock | Payment of exercise | Dispose F | No | No | 1.4 | 6,101 | 8.54 k | 149,364 |
17 Mar 24 | Megan C. Timmins | Common Stock | Payment of exercise | Dispose F | No | No | 1.4 | 3,137 | 4.39 k | 75,378 |
14 Mar 24 | Jesse Neri | Common Stock | Grant | Acquire A | No | No | 0 | 33,330 | 0.00 | 33,330 |
14 Mar 24 | Jesse Neri | Stock Option Common Stock | Grant | Acquire A | No | No | 1.39 | 47,190 | 65.59 k | 47,190 |
14 Mar 24 | Mark Strobeck | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 155,465 |
14 Mar 24 | Mark Strobeck | Stock Option Common Stock | Grant | Acquire A | No | No | 1.39 | 141,560 | 196.77 k | 141,560 |
14 Mar 24 | Megan C. Timmins | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 78,515 |
14 Mar 24 | Megan C. Timmins | Stock Option Common Stock | Grant | Acquire A | No | No | 1.39 | 70,780 | 98.38 k | 70,780 |
News
HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $9
25 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
22 Mar 24
Earnings Scheduled For March 21, 2024
21 Mar 24
Rockwell Medical: Q4 Earnings Insights
21 Mar 24
Rockwell Medical Q4 Adjusted EPS $0.02 May Not Be Comparable To $(0.07) Estimate, Sales $22.10M Miss $22.63M Estimate
21 Mar 24
Press releases
Rockwell Medical Named 'Great Place to Work' for Second Year in a Row
25 Mar 24
Universal Display Corporation Announces the Appointment of New Board Members
7 Mar 24
Rockwell Medical to Release Fourth Quarter and Full-Year 2023 Results on Thursday, March 21, 2024
8 Feb 24
Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund
8 Jan 24